CCRM
Stephanie Legere, Ph.D., currently serves as the Manager of Technology and Venture Development at CCRM, a position held since January 2022, following roles as Senior Venture Associate and Venture Associate II at the same organization. Previously, Stephanie was a Postdoctoral Fellow at adMare BioInnovations from March 2021 to December 2021. Stephanie earned a Doctor of Philosophy in Immunology from Dalhousie University between 2016 and 2021, and a Bachelor of Science in Microbiology and Immunology from the same institution from 2011 to 2015.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.